Trevi Raises $162M, Extends Runway to 2030 as Phase 3 Start Nears

What happened

Trevi Therapeutics completed a follow-on stock offering netting approximately $162 million, boosting its cash position and extending the expected runway into 2030 through potential FDA approval of Haduvio for IPF-related chronic cough. The company reported Q1 2026 financial results and reiterated that clinical development plans remain on track across all chronic cough indications. While management frames this as securing financing through key milestones, the offering adds significant dilution—coming on top of the 43% year-over-year share increase already noted in 2025. The extended runway reduces near-term bankruptcy risk but also implies that management expects high cash burn through multiple Phase 3 programs without near-term revenue. The market is likely to view the dilution negatively given the stock's already high premium, as the base-case valuation already assumed manageable cash needs.

Implication

Investors should recognize that this follow-on offering, while extending the cash runway into 2030, materially increases the share count and reduces per-share value of any future success. The $162 million raise—on top of the existing $195 million—now funds operations through potential approval, but at the cost of significant dilution that the stock price likely has not fully discounted. This move also suggests that management anticipates higher-than-expected trial costs or a longer timeline, consistent with our bear-case scenario of a more extensive IPF program. With the stock trading near our base-case valuation of $11.00 and the bull-case of $17.00 now requiring even greater revenue to compensate for diluted shares, risk/reward remains unfavorable. We recommend maintaining a cautious position and looking for entry points near our attractive entry of $8.50, as the extended runway does not change the fundamental binary risk of Phase 3 outcomes.

Thesis delta

The additional $162M equity raise extends the cash runway into 2030 but confirms our thesis that Trevi will require substantial capital before any revenue, increasing dilution risk. While this eliminates near-term financing overhang, it also signals that management expects high burn through Phase 3 and potential approval, consistent with our bear-case scenario of a more costly development path. The stock's elevated valuation now incorporates even more dilution, making the risk/reward even less attractive at current levels.